Radius Health, Inc.

NasdaqGM:RDUS Stock Report

Market Cap: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health Past Earnings Performance

Past criteria checks 0/6

Key information

28.59%

Earnings growth rate

30.13%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate35.32%
Return on equityn/a
Net Margin-30.72%
Last Earnings Update30 Jun 2022

Recent past performance updates

Recent updates

Radius Recycling's Surge Justifies A Reevaluation

Mar 14

Radius Recycling Will Benefit From Steel Tariffs

Feb 25

Radius Recycling Stays In The Scrap Pile

Jul 16

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Jun 03

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

Reevaluating Radius Health

Feb 24

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Feb 23
When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01
How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Revenue & Expenses Breakdown

How Radius Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:RDUS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 22223-69129121
31 Mar 22217-73127122
31 Dec 21230-70130131
30 Sep 21228-76138128
30 Jun 21249-60134134
31 Mar 21247-87140151
31 Dec 20239-109143159
30 Sep 20232-113144158
30 Jun 20200-136148149
31 Mar 20191-128150131
31 Dec 19173-133155115
30 Sep 19152-149163104
30 Jun 19133-169170100
31 Mar 19115-20317999
31 Dec 1899-22118698
30 Sep 1872-25119397
30 Jun 1858-25919791
31 Mar 1837-25919984
31 Dec 1722-25418981
30 Sep 1714-23616782
30 Jun 171-22413889
31 Mar 170-19910497
31 Dec 160-18380105
30 Sep 160-16362104
30 Jun 160-1455195
31 Mar 160-1254084
31 Dec 150-1023168

Quality Earnings: RDUS is currently unprofitable.

Growing Profit Margin: RDUS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/11 10:17
End of Day Share Price 2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Radius Health, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.